Recombinant Cynomolgus PARK2 Protein, His-tagged

• Cat.No.: PARK2-772C
• Product Overview: Recombinant Cynomolgus PARK2 full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Cynomolgus
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: PARK2 parkinson protein 2, E3 ubiquitin protein ligase (parkin) [ Macaca fascicularis (crab-eating macaque) ]
• Official Symbol: PARK2
• Synonyms: PARK2; parkin
• Gene ID: 102134446
• mRNA Refseq: NM_001287662
• Protein Refseq: NP_001274591
• UniProt ID: B8YGJ6

Reviews

04/18/2020

Their expertise and commitment to customer satisfaction make them a trusted partner in achieving research goals.

12/02/2016

Their knowledgeable team is readily available to address any questions or concerns, guaranteeing a smooth experimental process.

02/25/2016

the manufacturer of PARK2 protein provides excellent technical support, ensuring prompt assistance and guidance.

Q&As

Are there any other neurological disorders associated with PARK2 mutations?

Besides Parkinson's disease, PARK2 mutations have been linked to other neurodegenerative disorders, expanding the clinical implications of studying this protein.

Can PARK2 protein be a target for drug development in Parkinson's disease?

Yes, drug development efforts are underway to modulate PARK2 activity and enhance its neuroprotective functions as a potential therapeutic approach for Parkinson's disease.

In what ways does PARK2 protein research contribute to our understanding of mitochondrial dynamics in neurodegenerative diseases?

PARK2 research provides crucial insights into the role of mitochondrial dynamics in neurodegenerative diseases, helping unravel the mechanisms underlying these disorders and paving the way for targeted therapies.

How can genetic testing for PARK2 mutations aid in personalized medicine for Parkinson's patients?

Genetic testing can help identify individuals with PARK2 mutations, allowing for personalized treatment strategies tailored to their specific genetic profile.

How is PARK2 protein linked to the regulation of inflammation in the brain?

PARK2 is implicated in controlling inflammation in the brain, and its dysfunction may contribute to neuroinflammatory processes observed in Parkinson's disease.